糖尿病肾病检测和管理临床实践指南：西班牙肾病学会的共识文件

IF 2 4区医学 Q2 UROLOGY & NEPHROLOGY

Nefrologia Pub Date : 2024-11-17 DOI:10.1016/j.nefro.2024.11.002

Nuria Montero , Laia Oliveras , Alberto Martínez-Castelao , José Luis Gorriz , María José Soler , Beatriz Fernández-Fernández , María Quero , Clara García-Carro , Paula García-Sancho , Marian Goicechea , Juan José Gorgojo Martínez , Pablo Molina , María Jesús Puchades , Diana Rodríguez-Espinosa , Nery Sablón , Rafael Santamaría , Juan Francisco Navarro-González , en nombre del Grupo Español de Estudio de la Nefropatía Diabética (GEENDIAB)

{"title":"糖尿病肾病检测和管理临床实践指南：西班牙肾病学会的共识文件","authors":"Nuria Montero , Laia Oliveras , Alberto Martínez-Castelao , José Luis Gorriz , María José Soler , Beatriz Fernández-Fernández , María Quero , Clara García-Carro , Paula García-Sancho , Marian Goicechea , Juan José Gorgojo Martínez , Pablo Molina , María Jesús Puchades , Diana Rodríguez-Espinosa , Nery Sablón , Rafael Santamaría , Juan Francisco Navarro-González , en nombre del Grupo Español de Estudio de la Nefropatía Diabética (GEENDIAB)","doi":"10.1016/j.nefro.2024.11.002","DOIUrl":null,"url":null,"abstract":"<div><div>To address all the changes in the management of people with diabetes (DM) and chronic kidney disease (CKD), under the auspices of the Spanish Society of Nephrology (SEN), the Spanish Diabetic Nephropathy Study Group (GEENDIAB) decided to publish an updated Clinical Practice Guideline for detection and management of diabetic kidney disease (DKD). It is aimed at a wide audience of clinicians treating diabetes and CKD. The terminology of kidney disease in diabetic patients has evolved towards a more inclusive nomenclature that avoids underdiagnosis of this entity. Thus, the terms “diabetes and kidney disease” and “diabetic kidney disease” are those proposed in the latest KDIGO 2022 guidelines to designate the whole spectrum of patients who can benefit from a comprehensive therapeutic approach only differentiated according to eGFR range and albuminuria.</div><div>Recommendations have been divided into five main areas of interest: Chapter 1: Screening and diagnosis of diabetic kidney disease, Chapter 2: Metabolic control in people with diabetes and CKD, Chapter 3: Blood pressure control in people with diabetic kidney disease, Chapter 4: Treatment targeting progression of CKD in people with diabetic kidney disease, and Chapter 5: Antiplatelet or anticoagulant therapy in people with diabetes and CKD.</div><div>World Health Organization (WHO) recommendations for guideline development were followed to report this guideline. Systematic reviews were carried out, with outcome ratings and summaries of findings, and we reported the strength of recommendations following the “Grading of Recommendations Assessment, Development and Evaluation” GRADE evidence profiles.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 ","pages":"Pages 1-26"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Guía de práctica clínica sobre detección y manejo de la enfermedad renal diabética: documento de consenso de la Sociedad Española de Nefrología\",\"authors\":\"Nuria Montero , Laia Oliveras , Alberto Martínez-Castelao , José Luis Gorriz , María José Soler , Beatriz Fernández-Fernández , María Quero , Clara García-Carro , Paula García-Sancho , Marian Goicechea , Juan José Gorgojo Martínez , Pablo Molina , María Jesús Puchades , Diana Rodríguez-Espinosa , Nery Sablón , Rafael Santamaría , Juan Francisco Navarro-González , en nombre del Grupo Español de Estudio de la Nefropatía Diabética (GEENDIAB)\",\"doi\":\"10.1016/j.nefro.2024.11.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>To address all the changes in the management of people with diabetes (DM) and chronic kidney disease (CKD), under the auspices of the Spanish Society of Nephrology (SEN), the Spanish Diabetic Nephropathy Study Group (GEENDIAB) decided to publish an updated Clinical Practice Guideline for detection and management of diabetic kidney disease (DKD). It is aimed at a wide audience of clinicians treating diabetes and CKD. The terminology of kidney disease in diabetic patients has evolved towards a more inclusive nomenclature that avoids underdiagnosis of this entity. Thus, the terms “diabetes and kidney disease” and “diabetic kidney disease” are those proposed in the latest KDIGO 2022 guidelines to designate the whole spectrum of patients who can benefit from a comprehensive therapeutic approach only differentiated according to eGFR range and albuminuria.</div><div>Recommendations have been divided into five main areas of interest: Chapter 1: Screening and diagnosis of diabetic kidney disease, Chapter 2: Metabolic control in people with diabetes and CKD, Chapter 3: Blood pressure control in people with diabetic kidney disease, Chapter 4: Treatment targeting progression of CKD in people with diabetic kidney disease, and Chapter 5: Antiplatelet or anticoagulant therapy in people with diabetes and CKD.</div><div>World Health Organization (WHO) recommendations for guideline development were followed to report this guideline. Systematic reviews were carried out, with outcome ratings and summaries of findings, and we reported the strength of recommendations following the “Grading of Recommendations Assessment, Development and Evaluation” GRADE evidence profiles.</div></div>\",\"PeriodicalId\":18997,\"journal\":{\"name\":\"Nefrologia\",\"volume\":\"45 \",\"pages\":\"Pages 1-26\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-11-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nefrologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0211699524001115\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nefrologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0211699524001115","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

为了解决糖尿病（DM）和慢性肾脏疾病（CKD）患者管理的所有变化，在西班牙肾病学会（SEN）的主持下，西班牙糖尿病肾病研究组（GEENDIAB）决定发布更新的糖尿病肾病（DKD）检测和管理临床实践指南。它的目标是广泛的受众临床医生治疗糖尿病和慢性肾病。糖尿病患者肾脏疾病的术语已经演变成一个更具有包容性的命名法，以避免这个实体的诊断不足。因此，“糖尿病和肾脏疾病”和“糖尿病肾病”是最新的KDIGO 2022指南中提出的术语，用于指定可从仅根据eGFR范围和蛋白尿区分的综合治疗方法中获益的全谱患者。建议分为五个主要领域：第1章：糖尿病肾病的筛查和诊断，第2章：糖尿病和CKD患者的代谢控制，第3章：糖尿病肾病患者的血压控制，第4章：针对糖尿病肾病患者CKD进展的治疗，第5章：糖尿病和CKD患者的抗血小板或抗凝治疗。遵循世界卫生组织（WHO）关于指南制定的建议，报告了本指南。进行了系统评价，包括结果评级和结果摘要，并根据“建议评估、发展和评价的分级”GRADE证据概要报告了建议的强度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Guía de práctica clínica sobre detección y manejo de la enfermedad renal diabética: documento de consenso de la Sociedad Española de Nefrología

To address all the changes in the management of people with diabetes (DM) and chronic kidney disease (CKD), under the auspices of the Spanish Society of Nephrology (SEN), the Spanish Diabetic Nephropathy Study Group (GEENDIAB) decided to publish an updated Clinical Practice Guideline for detection and management of diabetic kidney disease (DKD). It is aimed at a wide audience of clinicians treating diabetes and CKD. The terminology of kidney disease in diabetic patients has evolved towards a more inclusive nomenclature that avoids underdiagnosis of this entity. Thus, the terms “diabetes and kidney disease” and “diabetic kidney disease” are those proposed in the latest KDIGO 2022 guidelines to designate the whole spectrum of patients who can benefit from a comprehensive therapeutic approach only differentiated according to eGFR range and albuminuria.

Recommendations have been divided into five main areas of interest: Chapter 1: Screening and diagnosis of diabetic kidney disease, Chapter 2: Metabolic control in people with diabetes and CKD, Chapter 3: Blood pressure control in people with diabetic kidney disease, Chapter 4: Treatment targeting progression of CKD in people with diabetic kidney disease, and Chapter 5: Antiplatelet or anticoagulant therapy in people with diabetes and CKD.

World Health Organization (WHO) recommendations for guideline development were followed to report this guideline. Systematic reviews were carried out, with outcome ratings and summaries of findings, and we reported the strength of recommendations following the “Grading of Recommendations Assessment, Development and Evaluation” GRADE evidence profiles.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nefrologia 医学-泌尿学与肾脏学

CiteScore

3.40

自引率

7.70%

发文量

148

审稿时长

47 days

期刊介绍： Nefrología is the official publication of the Spanish Society of Nephrology. The Journal publishes articles on basic or clinical research relating to nephrology, arterial hypertension, dialysis and kidney transplants. It is governed by the peer review system and all original papers are subject to internal assessment and external reviews. The journal accepts submissions of articles in English and in Spanish languages.